Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation
International Journal of Nanomedicine · 2026-09 · Volume 21 · 1-32
DOI: 10.2147/ijn.s627669 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-09. Verfasst von Jinyang An und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Osteoporosis, Nanomedicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Osteoporosis is influenced by signals from multiple tissues and body systems. Extracellular vesicles (EVs) and EV-like particles may contribute to bone remodeling, serve as biomarkers, or act as therapeutic delivery platforms, but these distinct research settings are often conflated and their evidential and translational maturity remains unclear.
Objective
To map research on non-bone-derived EVs and EV-like particles in osteoporosis-related bone remodeling using a purpose-based framework and to assess source and cargo attribution, evidence strength, and translational stage.
Methods
PubMed, Web of Science Core Collection, and EMBASE were searched from inception to July 15, 2026, supplemented by citation searching. Eligible original studies evaluated bone-related cellular or remodeling outcomes, clinically relevant bone phenotypes, biomarker associations, or therapeutic and delivery effects. Studies were classified as mechanism-, biomarker-, or intervention/delivery-focused, graded using an operational A-C evidence framework, and stratified from T0 to T3.
Results
We included 114 studies: 39 mechanism-focused, 22 biomarker-focused, and 53 intervention/delivery-focused. Most evidence remained preclinical, with 24 T0 and 76 T1 studies; 14 studies reached participant-level T2 evidence. Although 55 studies met level C criteria, EV dependence, cargo attribution, and endogenous source-to-bone attribution represented distinct and non-interchangeable dimensions, and strict in vivo source-to-bone attribution remained uncommon. In the bibliographic databases searched, no eligible published clinical or industrial evidence at T3 was identified. External validation of human biomarkers, biodistribution assessment, standardized potency assays, and product-level quality control were also uncommon.
Conclusion
Non-bone-derived EVs and EV-like particles should be interpreted as a purpose-stratified evidence landscape rather than as a single biological mechanism. Current findings provide an evidence-organizing framework, not clinically ready diagnostic or therapeutic platforms. Priorities include stronger source tracing and cargo attribution, longitudinal human validation, quantitative biodistribution and potency assessment, and GMP-compatible product development. People with osteoporosis have weaker bones and a higher risk of fractures. Signals from muscles, fat tissue, blood vessels, immune cells, and microorganisms may also affect bone health. Some of these signals are carried by tiny membrane-bound particles called extracellular vesicles, or EVs. We reviewed 114 studies. We separated studies that examined how EVs may affect bone, whether EVs in blood or urine could help assess bone health, and whether EVs could be used as treatments or to carry medicines. Most evidence came from studies in cells or animals. Few studies involved people with osteoporosis or related bone-loss conditions, and strong proof that EVs travel from a specific tissue to bone was uncommon. In the databases searched, we found no eligible published evidence of routine clinical use or established product development. EV-based tests and treatments are not yet ready to guide routine care for people with osteoporosis. Better human studies, clearer tracking of where EVs come from and where they travel, and reliable methods to produce and test them are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China.
- Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai, People's Republic of China.
- Gansu Clinical Medical Research Center for Endocrine Diseases, Lanzhou, Gansu, People's Republic of China.
ORCID-Profile: Jinyang An, Xinsai Li, Ying Yang, Yangyang Zhang, Shuyun Li, Mingming Jin, Haihong Lv
Zitieren
APA
An, J., Li, X., Yang, Y., Zhang, Y., Li, S., Jin, M., & Lv, H. (2026). Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation. International Journal of Nanomedicine, Volume 21, 1-32. https://doi.org/10.2147/ijn.s627669
Vancouver
An J, Li X, Yang Y, Zhang Y, Li S, Jin M, et al. Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation. International Journal of Nanomedicine. 2026;Volume 21:1-32. doi:10.2147/ijn.s627669
BibTeX
@article{An2026,
author = {An, Jinyang and Li, Xinsai and Yang, Ying and Zhang, Yangyang and Li, Shuyun and Jin, Mingming and Lv, Haihong},
title = {Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--32},
doi = {10.2147/ijn.s627669}
}
EUVIMED